Every week, I travel the world [wide web] in search of interesting new biotech developments. This week, a smattering of stories from Canada, the U.S. and China are worth noting:
In Canada (and presumably elsewhere as well) Merck put out a country-specific press release announcing the closing of its merger with Schering-Plough. Merck calls Canada “an integral part of the company’s expanded global presence.”
In the U.S., Congress decided that the shutdown of (Canada’s) Chalk River reactor was a warning, and passed a bill to stimulate domestic production of medical isotopes. About 60% of the U.S. supply had been coming from the AECL facility.
In China, all signs point to the country joining the ranks of countries advocating strong IP rights. This week, a study showed China’s research output doubling since 2004 and a Forbes article noted a copyright enforcement action by Chinese authors. Not a coincidence.